![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Maat Pharma SA | EU:MAAT | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.04 | -0.53% | 7.50 | 7.50 | 7.56 | 7.58 | 7.50 | 7.56 | 231 | 16:35:25 |
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announces its half-year report on the liquidity contract with the firm Kepler Cheuvreux and an increase of €50,000 to the resources allocated to the contract, in accordance with the provisions of article 4 of AMF decision no. 2021-01 of June 22, 2021.
Under the liquidity contract entered into between Maat Pharma and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th, 2024:
As a reminder:
Following the addition of these resources for the amount of €50,000, the position on July 4th, 2024, is:
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.
Buy Side Sell Side Number ofexecutions Number ofshares Tradedvolume inEUR Number ofexecutions Number ofshares Tradedvolume inEUR Total933
28,959
237,891.32
1,014
26,266
220,168.07
02/01/2024-
-
-
9
102
719.10
03/01/20243
60
448.80
15
435
3,275.55
04/01/20249
126
948.78
8
211
1,612.04
05/01/20242
45
339.30
3
90
689.40
08/01/202418
410
2,886.40
-
-
-
09/01/202411
340
2,237.20
15
425
2,843.25
10/01/20245
130
877.50
2
72
487.44
11/01/20242
2
13.74
10
241
1,679.77
12/01/20244
50
351.00
2
70
501.20
15/01/20248
203
1,408.82
8
110
779.90
16/01/20243
36
252.00
3
35
246.40
17/01/20245
70
482.30
-
-
-
18/01/20245
151
1,026.80
-
-
-
19/01/202410
222
1,469.64
1
30
201.00
22/01/20243
50
351.00
27
641
4,512.64
23/01/2024-
-
-
5
93
672.39
24/01/20247
175
1,242.50
4
130
928.20
25/01/20245
71
506.94
2
36
257.76
26/01/20243
10
71.50
4
93
668.67
29/01/20247
141
1,022.25
8
155
1,148.55
30/01/20242
21
151.20
2
36
260.64
31/01/20244
110
784.30
6
148
1,061.16
01/02/20243
60
430.80
2
42
304.50
02/02/20248
160
1,142.40
8
150
1,087.50
05/02/2024-
-
-
2
35
250.95
06/02/20243
70
497.00
5
105
753.90
07/02/20244
85
606.05
-
-
-
08/02/20242
21
149.94
5
83
593.45
09/02/202410
185
1,311.65
6
118
859.04
12/02/20247
127
896.62
1
1
7.22
13/02/20241
1
7.02
4
24
169.44
14/02/20244
69
481.62
2
32
227.20
15/02/20243
26
182.52
10
151
1,069.08
16/02/20242
30
213.00
3
41
293.15
19/02/20247
130
928.20
17
280
2,027.20
20/02/2024-
-
-
15
329
2,470.79
21/02/20249
130
964.60
-
-
-
22/02/2024-
-
-
9
115
865.95
23/02/20241
1
7.62
53
1,131
9,398.61
26/02/202426
550
4,526.50
9
103
850.78
27/02/20246
75
612.00
13
277
2,310.18
28/02/202445
880
6,758.40
23
706
5,655.06
29/02/202415
211
1,673.23
3
34
270.30
01/03/20244
90
711.00
10
200
1,606.00
04/03/202414
260
2,048.80
7
130
1,036.10
05/03/20249
162
1,263.60
10
133
1,046.71
06/03/202411
245
2,035.95
53
1,009
8,465.51
07/03/20242
20
170.40
21
260
2,236.00
08/03/202417
335
2,814.00
6
94
797.12
11/03/20247
114
992.94
22
381
3,341.37
12/03/20247
139
1,234.32
10
316
2,837.68
13/03/20241
35
315.00
25
1,039
9,735.43
14/03/202430
921
8,427.15
13
319
2,992.22
15/03/202411
291
2,697.57
28
632
5,890.24
18/03/20245
99
903.87
3
45
413.55
19/03/2024-
-
-
6
74
682.28
20/03/202420
553
4,943.82
13
328
2,971.68
21/03/20248
370
3,204.20
3
55
480.70
22/03/20246
125
1,113.75
19
422
3,798.00
25/03/202412
193
1,796.83
16
481
4,540.64
26/03/20246
158
1,448.86
8
173
1,600.25
27/03/20241
50
465.00
6
258
2,414.88
28/03/202422
692
6,304.12
8
343
3,217.34
02/04/20245
185
1,626.15
6
185
1,635.40
03/04/20244
56
495.60
1
1
8.86
04/04/2024-
-
-
4
90
808.20
05/04/2024-
-
-
17
435
4,023.75
08/04/20249
256
2,403.84
26
626
5,959.52
09/04/20248
133
1,263.50
10
444
4,253.52
10/04/2024-
-
-
7
226
2,171.86
11/04/20242
36
342.00
5
33
316.47
12/04/20242
20
189.60
1
1
9.56
15/04/202441
1,314
12,246.48
25
785
7,622.35
16/04/20244
125
1,140.00
14
325
2,996.50
17/04/202413
578
5,138.42
-
-
-
18/04/20243
101
906.98
5
266
2,420.60
19/04/202421
1,779
15,726.36
7
304
2,723.84
22/04/20244
330
2,864.40
11
593
5,200.61
23/04/20243
124
1,088.72
6
157
1,389.45
24/04/20246
217
1,907.43
2
2
17.62
25/04/20241
1
8.80
12
468
4,165.20
26/04/20242
130
1,170.00
3
29
262.74
29/04/20246
285
2,676.15
20
652
6,109.24
30/04/20246
354
3,313.44
3
105
996.45
02/05/20245
221
2,048.67
2
80
747.20
03/05/20241
1
9.24
7
264
2,460.48
06/05/202410
323
3,007.13
4
91
849.94
07/05/20244
244
2,286.28
12
466
4,385.06
08/05/20241
20
188.00
1
5
47.30
09/05/2024-
-
-
1
95
898.70
10/05/20246
161
1,513.40
2
39
368.94
13/05/20242
103
968.20
2
101
952.43
14/05/20242
77
719.18
2
84
788.76
15/05/202455
3,305
27,695.90
5
150
1,281.00
16/05/20247
340
2,692.80
9
260
2,072.20
17/05/202412
387
3,154.05
15
325
2,668.25
20/05/20248
325
2,665.00
7
205
1,693.30
21/05/20247
265
2,130.60
4
200
1,624.00
22/05/202411
344
2,752.00
3
88
719.84
23/05/20243
62
494.76
6
130
1,040.00
24/05/20246
308
2,439.36
8
230
1,826.20
27/05/20241
15
119.10
2
80
640.80
28/05/20242
70
558.60
3
55
443.30
29/05/20248
212
1,704.48
5
129
1,046.19
30/05/20248
313
2,500.87
4
88
709.28
31/05/20248
451
3,598.98
1
1
8.04
03/06/20243
150
1,194.00
3
50
400.00
04/06/20246
200
1,586.00
4
110
875.60
05/06/20245
119
940.10
5
100
794.00
06/06/20247
250
1,970.00
1
1
7.94
07/06/20246
214
1,697.02
8
140
1,113.00
10/06/20249
305
2,400.35
1
40
316.80
11/06/20245
200
1,560.00
5
212
1,670.56
12/06/20243
105
807.45
1
50
385.00
13/06/20245
163
1,253.47
4
125
965.00
14/06/202417
440
3,291.20
2
57
434.91
17/06/202426
700
4,704.00
6
285
1,915.20
18/06/20243
60
403.80
7
355
2,410.45
19/06/202410
591
3,953.79
3
39
267.54
20/06/20244
68
450.84
7
150
1,009.50
21/06/20242
51
346.80
5
303
2,084.64
24/06/20241
19
131.10
7
174
1,211.04
25/06/20247
150
1,081.50
10
360
2,610.00
26/06/2024-
-
-
26
944
7,174.40
27/06/202419
613
4,677.19
4
89
688.86
28/06/202423
904
6,535.92
4
187
1,357.62
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).
View source version on businesswire.com: https://www.businesswire.com/news/home/20240705981889/en/
MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D. Head of Investor Relations +33 6 16 48 92 50 invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR & Corporate Communications Manager +33 6 14 06 45 92 media@maat-pharma.com
Trophic Communications Jacob VERGHESE or Desmond JAMES +49 151 7441 6179 maat@trophic.eu
1 Year Maat Pharma Chart |
1 Month Maat Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions